Sagimet Biosciences Inc Series A (SGMT)

$5.42 +0.12 (2.26%)
Market Cap 172.70M
Revenue (ttm) 0.00
Net Income (ttm) -51.04M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE N/A
Profit Margin 0.00%
Debt to Equity Ratio 0.00
Volume 330,900
Avg Vol 478,860
Day's Range N/A - N/A
Shares Out 32.59M
Stochastic %K 74%
Beta 3.17
Analysts Strong Sell
Price Target $27.00

Company Profile

Sagimet Biosciences Inc., a clinical-stage biopharmaceutical company, develops novel therapeutics called fatty acid synthase (FASN) inhibitors for the treatment of diseases that result from dysfunctional metabolic and fibrotic pathways in the United States. The company's lead drug candidate is Denifanstat, an oral, once-daily pill and selective FASN inhibitor for the treatment of metabolic dysfunction-associated steatohepatitis, acne, and select forms of cancer. It also develops TVB-3567, a FASN...

Industry: Biotechnology
Sector: Healthcare
Phone: 650 561 8600
Address:
155 Bovet Road, Suite 303, San Mateo, United States
buymoremakemore
buymoremakemore Apr. 10 at 1:14 PM
$SGMT Added another 10k shares. Now sitting at 50k shares. Big things about to happen in H2 to take this over $10. Good phase 3 china data briefly took this over $10. We will return there and an offer of $20 or $30 wont be so crazy in next 2 years
1 · Reply
SYC80
SYC80 Apr. 9 at 7:59 PM
$SGMT — tick tock… ⏳ H2 is where it gets interesting. Staying patient.
0 · Reply
rational1
rational1 Apr. 9 at 3:06 PM
$SGMT Canaccord - Come for MASH, but stay for acne Reiterates buy & $28 PT https://my.apps.factset.com/viewer/?_expand=jN6Nd9X&float_window=true
1 · Reply
Biostock
Biostock Apr. 9 at 2:14 PM
$SGMT $XBI $LABU $QQQ $SPY
0 · Reply
Biostock
Biostock Apr. 8 at 5:05 PM
$SGMT MASH and ACNE. Billions in TAM. Big pharma paid billions to acquire AKRO and ETNB 's MASH program. $XBI $LABU $QQQ $SPY
1 · Reply
Biostock
Biostock Apr. 8 at 3:21 PM
$SGMT $XBI $LABU $SPY $QQQ
0 · Reply
Whiskeyunderthebed
Whiskeyunderthebed Apr. 8 at 2:59 PM
$SGMT nice move today
0 · Reply
focafoca99
focafoca99 Apr. 6 at 6:23 PM
$SGMT is combining science and HR here, highlighting upcoming MASH presentations while also disclosing an inducement grant.
0 · Reply
Biostock
Biostock Apr. 6 at 5:12 PM
$SGMT 27. MASH and ACNE. Billions in TAM. $XBI $LABU $SPY $QQQ up
0 · Reply
julsa
julsa Apr. 6 at 4:50 PM
$SGMT https://ir.sagimet.com/news-releases/news-release-details/sagimet-biosciences-announces-poster-and-oral-presentations
0 · Reply
Latest News on SGMT
Sagimet Biosciences Announces Poster and Oral Presentations at the Fueling MASH: Metabolic Drivers and Inflammatory Crosstalk Keystone Symposium and Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

Apr 6, 2026, 7:00 AM EDT - 7 days ago

Sagimet Biosciences Announces Poster and Oral Presentations at the Fueling MASH: Metabolic Drivers and Inflammatory Crosstalk Keystone Symposium and Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

Sagimet Biosciences Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Corporate Updates

Mar 11, 2026, 7:30 AM EDT - 4 weeks ago

Sagimet Biosciences Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Corporate Updates

Sagimet Biosciences Announces Participation in Three Upcoming Investor Conferences

Feb 25, 2026, 7:00 AM EST - 6 weeks ago

Sagimet Biosciences Announces Participation in Three Upcoming Investor Conferences

Sagimet Biosciences Announces Participation in Two Upcoming Investor Conferences

Feb 5, 2026, 7:00 AM EST - 2 months ago

Sagimet Biosciences Announces Participation in Two Upcoming Investor Conferences

Sagimet Announces Positive 52-Week Data from License Partner Ascletis' Open-Label Phase 3 Clinical Trial Evaluating the Long-Term Safety of ASC40 (Denifanstat) Tablets in Patients with Moderate to Severe Acne

Feb 2, 2026, 7:00 AM EST - 2 months ago

Sagimet Announces Positive 52-Week Data from License Partner Ascletis' Open-Label Phase 3 Clinical Trial Evaluating the Long-Term Safety of ASC40 (Denifanstat) Tablets in Patients with Moderate to Severe Acne

Ascletis Announces Positive Topline Results from Its Phase III Open-Label Study of Denifanstat (ASC40), a First-in-Class, Once-Daily Oral FASN Inhibitor for Acne

Jan 29, 2026, 6:00 AM EST - 2 months ago

Ascletis Announces Positive Topline Results from Its Phase III Open-Label Study of Denifanstat (ASC40), a First-in-Class, Once-Daily Oral FASN Inhibitor for Acne

Biotech Veteran and Virologist Joins CancerVax as Senior Scientific Advisor

Jan 27, 2026, 3:00 AM EST - 2 months ago

Biotech Veteran and Virologist Joins CancerVax as Senior Scientific Advisor

Sagimet Biosciences Announces Poster Presentation at the 10th Annual MASH-TAG 2026 Conference

Jan 8, 2026, 7:00 AM EST - 3 months ago

Sagimet Biosciences Announces Poster Presentation at the 10th Annual MASH-TAG 2026 Conference

Sagimet Biosciences Announces Positive Results from the Phase 1 PK Clinical Trial of Denifanstat and Resmetirom Combination

Dec 18, 2025, 7:00 AM EST - 4 months ago

Sagimet Biosciences Announces Positive Results from the Phase 1 PK Clinical Trial of Denifanstat and Resmetirom Combination

Sagimet's License Partner Ascletis Announced Acceptance of New Drug Application for Denifanstat for the Treatment of Moderate to Severe Acne by China's National Medical Products Administration

Dec 10, 2025, 7:03 AM EST - 4 months ago

Sagimet's License Partner Ascletis Announced Acceptance of New Drug Application for Denifanstat for the Treatment of Moderate to Severe Acne by China's National Medical Products Administration

Ascletis Announces China National Medical Products Administration Acceptance of New Drug Application for Denifanstat (ASC40), a First-in-Class FASN Inhibitor for Acne Treatment

Dec 10, 2025, 4:15 AM EST - 4 months ago

Ascletis Announces China National Medical Products Administration Acceptance of New Drug Application for Denifanstat (ASC40), a First-in-Class FASN Inhibitor for Acne Treatment

Sagimet Biosciences Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Dec 9, 2025, 4:05 PM EST - 4 months ago

Sagimet Biosciences Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Sagimet Biosciences to Participate in the 8th Annual Evercore ISI Healthcare Conference

Nov 20, 2025, 7:00 AM EST - 5 months ago

Sagimet Biosciences to Participate in the 8th Annual Evercore ISI Healthcare Conference

Sagimet Biosciences Presents Two Denifanstat Posters at AASLD—The Liver Meeting® 2025

Nov 10, 2025, 7:00 AM EST - 5 months ago

Sagimet Biosciences Presents Two Denifanstat Posters at AASLD—The Liver Meeting® 2025

Denifanstat Achieved All Endpoints in the Treatment of Moderate to Severe Acne in Phase 3 Clinical Trial in Acne in China: A Presentation at the 2025 Fall Clinical Dermatology Conference

Oct 24, 2025, 7:00 AM EDT - 6 months ago

Denifanstat Achieved All Endpoints in the Treatment of Moderate to Severe Acne in Phase 3 Clinical Trial in Acne in China: A Presentation at the 2025 Fall Clinical Dermatology Conference

Ascletis Completes Denifanstat (ASC40) Pre-NDA Consultation with China National Medical Products Administration

Oct 14, 2025, 6:00 AM EDT - 6 months ago

Ascletis Completes Denifanstat (ASC40) Pre-NDA Consultation with China National Medical Products Administration

Sagimet Biosciences Announces Upcoming Presentation at AASLD—The Liver Meeting® 2025

Oct 7, 2025, 7:00 AM EDT - 6 months ago

Sagimet Biosciences Announces Upcoming Presentation at AASLD—The Liver Meeting® 2025

Positive Phase 3 Results for Denifanstat for the Treatment of Moderate to Severe Acne to be Presented at the EADV Congress 2025 by Partner Ascletis

Sep 17, 2025, 7:00 AM EDT - 7 months ago

Positive Phase 3 Results for Denifanstat for the Treatment of Moderate to Severe Acne to be Presented at the EADV Congress 2025 by Partner Ascletis

Sagimet Biosciences Announces Upcoming Presentations at 9th Annual MASH Drug Development Summit

Sep 10, 2025, 7:00 AM EDT - 7 months ago

Sagimet Biosciences Announces Upcoming Presentations at 9th Annual MASH Drug Development Summit

Sagimet Biosciences to Participate in Two Upcoming Investor Conferences

Aug 26, 2025, 7:00 AM EDT - 8 months ago

Sagimet Biosciences to Participate in Two Upcoming Investor Conferences

Sagimet Biosciences Reports Second Quarter 2025 Financial Results and Provides Corporate Updates

Aug 13, 2025, 7:30 AM EDT - 8 months ago

Sagimet Biosciences Reports Second Quarter 2025 Financial Results and Provides Corporate Updates

Sagimet Biosciences to Participate in the Canaccord Genuity 45th Annual Growth Conference

Aug 5, 2025, 7:00 AM EDT - 8 months ago

Sagimet Biosciences to Participate in the Canaccord Genuity 45th Annual Growth Conference

Sagimet Biosciences to Host Virtual KOL Event, “A New Mechanism of Action in Treating Acne: Update on Positive Phase 3 Denifanstat Trial for the Treatment of Moderate to Severe Acne” on June 16, 2025

Jun 9, 2025, 7:00 AM EDT - 11 months ago

Sagimet Biosciences to Host Virtual KOL Event, “A New Mechanism of Action in Treating Acne: Update on Positive Phase 3 Denifanstat Trial for the Treatment of Moderate to Severe Acne” on June 16, 2025

Sagimet Biosciences Announces Positive Phase 3 Results for Denifanstat for the Treatment of Moderate-to-Severe Acne from Partner Ascletis

Jun 4, 2025, 5:00 AM EDT - 11 months ago

Sagimet Biosciences Announces Positive Phase 3 Results for Denifanstat for the Treatment of Moderate-to-Severe Acne from Partner Ascletis

Sagimet Biosciences to Host Virtual KOL Event, “Evaluating the Synergistic Potential of a Combination of Denifanstat and Resmetirom for the Treatment of Metabolic Dysfunction-Associated Steatohepatitis (MASH)” on May 29, 2025

May 22, 2025, 8:00 AM EDT - 11 months ago

Sagimet Biosciences to Host Virtual KOL Event, “Evaluating the Synergistic Potential of a Combination of Denifanstat and Resmetirom for the Treatment of Metabolic Dysfunction-Associated Steatohepatitis (MASH)” on May 29, 2025

Sagimet Biosciences Reports First Quarter 2025 Financial Results and Provides Corporate Updates

May 8, 2025, 6:00 AM EDT - 1 year ago

Sagimet Biosciences Reports First Quarter 2025 Financial Results and Provides Corporate Updates

Sagimet Biosciences Reports Full Year 2024 Financial Results and Provides Corporate Updates

Mar 12, 2025, 7:30 AM EDT - 1 year ago

Sagimet Biosciences Reports Full Year 2024 Financial Results and Provides Corporate Updates

Sagimet Biosciences Announces Clearance of IND for FASN Inhibitor TVB-3567, to be Developed for the Treatment of Acne

Mar 11, 2025, 8:00 AM EDT - 1 year ago

Sagimet Biosciences Announces Clearance of IND for FASN Inhibitor TVB-3567, to be Developed for the Treatment of Acne

Ascletis Completes Enrollment of Phase III Trial of ASC40 (Denifanstat) Once-Daily Oral Tablet for Treatment of Acne

Nov 12, 2024, 6:30 AM EST - 1 year ago

Ascletis Completes Enrollment of Phase III Trial of ASC40 (Denifanstat) Once-Daily Oral Tablet for Treatment of Acne

Sagimet Biosciences Announces Publication of Results from Phase 2b FASCINATE-2 Clinical Trial of Denifanstat in Biopsy-Confirmed F2/F3 MASH in The Lancet Gastroenterology & Hepatology

Oct 11, 2024, 7:00 AM EDT - 1 year ago

Sagimet Biosciences Announces Publication of Results from Phase 2b FASCINATE-2 Clinical Trial of Denifanstat in Biopsy-Confirmed F2/F3 MASH in The Lancet Gastroenterology & Hepatology

Sagimet Receives FDA Breakthrough Therapy Designation for Denifanstat in MASH

Oct 1, 2024, 7:00 AM EDT - 1 year ago

Sagimet Receives FDA Breakthrough Therapy Designation for Denifanstat in MASH

Sagimet Biosciences to Present at the H.C. Wainwright 8th Annual MASH Virtual Conference and Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Oct 1, 2024, 12:05 AM EDT - 1 year ago

Sagimet Biosciences to Present at the H.C. Wainwright 8th Annual MASH Virtual Conference and Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Sagimet Announces Oral Presentation at the 8th Annual MASH Drug Development Summit

Sep 12, 2024, 7:30 AM EDT - 1 year ago

Sagimet Announces Oral Presentation at the 8th Annual MASH Drug Development Summit

Sagimet Biosciences Announces Appointment of Anne Phillips and Jennifer Jarrett to its Board of Directors

Aug 1, 2024, 8:00 AM EDT - 1 year ago

Sagimet Biosciences Announces Appointment of Anne Phillips and Jennifer Jarrett to its Board of Directors

Sagimet Biosciences to Host Conference Call and Webcast to Discuss Recently Presented Data from ITT and F3 Patient Population in Phase 2b FASCINATE-2 Clinical Trial of Denifanstat

Jun 10, 2024, 8:00 AM EDT - 2 years ago

Sagimet Biosciences to Host Conference Call and Webcast to Discuss Recently Presented Data from ITT and F3 Patient Population in Phase 2b FASCINATE-2 Clinical Trial of Denifanstat

Sagimet Biosciences Presents Data from ITT and F3 Patient Population in Phase 2b FASCINATE-2 Clinical Trial of Denifanstat at EASL International Liver Congress 2024

Jun 6, 2024, 5:00 AM EDT - 2 years ago

Sagimet Biosciences Presents Data from ITT and F3 Patient Population in Phase 2b FASCINATE-2 Clinical Trial of Denifanstat at EASL International Liver Congress 2024

Sagimet Biosciences to Host Virtual Investor and Analyst Day on Inhibiting Fatty Acid Synthase (FASN) to Reduce Liver Fat, Inflammation and Fibrosis in MASH on May 23, 2024

May 16, 2024, 8:00 AM EDT - 2 years ago

Sagimet Biosciences to Host Virtual Investor and Analyst Day on Inhibiting Fatty Acid Synthase (FASN) to Reduce Liver Fat, Inflammation and Fibrosis in MASH on May 23, 2024

Sagimet Biosciences Reports First Quarter 2024 Financial Results and Provides Corporate Updates

May 15, 2024, 8:00 AM EDT - 2 years ago

Sagimet Biosciences Reports First Quarter 2024 Financial Results and Provides Corporate Updates

Sagimet Announces Oral Presentation of Data from the Phase 2b FASCINATE-2 Study of Denifanstat in MASH at EASL International Liver Congress 2024

May 7, 2024, 8:00 AM EDT - 2 years ago

Sagimet Announces Oral Presentation of Data from the Phase 2b FASCINATE-2 Study of Denifanstat in MASH at EASL International Liver Congress 2024

Sagimet Biosciences Announces Appointment of Thierry Chauche as Chief Financial Officer

May 6, 2024, 8:00 AM EDT - 2 years ago

Sagimet Biosciences Announces Appointment of Thierry Chauche as Chief Financial Officer

Sagimet Biosciences to Host Virtual Investor and Analyst Day on Inhibiting Fatty Acid Synthase (FASN) to Reduce Liver Fat, Inflammation and Fibrosis in MASH on May 3, 2024

Apr 22, 2024, 8:00 AM EDT - 2 years ago

Sagimet Biosciences to Host Virtual Investor and Analyst Day on Inhibiting Fatty Acid Synthase (FASN) to Reduce Liver Fat, Inflammation and Fibrosis in MASH on May 3, 2024

Sagimet Biosciences Announces Completion of Phase 1 Hepatic Impairment Study with FASN Inhibitor Denifanstat

Mar 27, 2024, 4:01 PM EDT - 2 years ago

Sagimet Biosciences Announces Completion of Phase 1 Hepatic Impairment Study with FASN Inhibitor Denifanstat

Sagimet Biosciences Announces Appointment of Tim Walbert and Paul Hoelscher to its Board of Directors

Mar 25, 2024, 7:00 AM EDT - 2 years ago

Sagimet Biosciences Announces Appointment of Tim Walbert and Paul Hoelscher to its Board of Directors

Sagimet Biosciences Reports Full Year 2023 Financial Results and Provides Corporate Updates

Mar 25, 2024, 6:15 AM EDT - 2 years ago

Sagimet Biosciences Reports Full Year 2023 Financial Results and Provides Corporate Updates

Sagimet Biosciences Announces Pricing of Public Offering of Series A Common Stock

Jan 25, 2024, 8:58 PM EST - 2 years ago

Sagimet Biosciences Announces Pricing of Public Offering of Series A Common Stock

Sagimet Biosciences Announces Proposed Public Offering of Series A Common Stock

Jan 23, 2024, 5:45 PM EST - 2 years ago

Sagimet Biosciences Announces Proposed Public Offering of Series A Common Stock

Gannex's Strategic Partner Sagimet Biosciences Announces Positive Topline Results from Phase 2b FASCINATE-2 Clinical Trial of Denifanstat in Biopsy-Confirmed F2/F3 NASH

Jan 22, 2024, 11:10 PM EST - 2 years ago

Gannex's Strategic Partner Sagimet Biosciences Announces Positive Topline Results from Phase 2b FASCINATE-2 Clinical Trial of Denifanstat in Biopsy-Confirmed F2/F3 NASH

Sagimet Biosciences Announces Positive Topline Results from Phase 2b FASCINATE-2 Clinical Trial of Denifanstat in Biopsy-Confirmed F2/F3 NASH

Jan 22, 2024, 7:00 AM EST - 2 years ago

Sagimet Biosciences Announces Positive Topline Results from Phase 2b FASCINATE-2 Clinical Trial of Denifanstat in Biopsy-Confirmed F2/F3 NASH

Sagimet Biosciences to Participate in the First Annual Goldman Sachs Catalyst Clinic

Dec 4, 2023, 8:00 AM EST - 2 years ago

Sagimet Biosciences to Participate in the First Annual Goldman Sachs Catalyst Clinic

Sagimet Biosciences Announces Oral Presentation of Preclinical Results of FASN Inhibitor in Combination with Semaglutide at the 7th Obesity and NASH Drug Development Summit

Nov 28, 2023, 8:00 AM EST - 2 years ago

Sagimet Biosciences Announces Oral Presentation of Preclinical Results of FASN Inhibitor in Combination with Semaglutide at the 7th Obesity and NASH Drug Development Summit

buymoremakemore
buymoremakemore Apr. 10 at 1:14 PM
$SGMT Added another 10k shares. Now sitting at 50k shares. Big things about to happen in H2 to take this over $10. Good phase 3 china data briefly took this over $10. We will return there and an offer of $20 or $30 wont be so crazy in next 2 years
1 · Reply
SYC80
SYC80 Apr. 9 at 7:59 PM
$SGMT — tick tock… ⏳ H2 is where it gets interesting. Staying patient.
0 · Reply
rational1
rational1 Apr. 9 at 3:06 PM
$SGMT Canaccord - Come for MASH, but stay for acne Reiterates buy & $28 PT https://my.apps.factset.com/viewer/?_expand=jN6Nd9X&float_window=true
1 · Reply
Biostock
Biostock Apr. 9 at 2:14 PM
$SGMT $XBI $LABU $QQQ $SPY
0 · Reply
Biostock
Biostock Apr. 8 at 5:05 PM
$SGMT MASH and ACNE. Billions in TAM. Big pharma paid billions to acquire AKRO and ETNB 's MASH program. $XBI $LABU $QQQ $SPY
1 · Reply
Biostock
Biostock Apr. 8 at 3:21 PM
$SGMT $XBI $LABU $SPY $QQQ
0 · Reply
Whiskeyunderthebed
Whiskeyunderthebed Apr. 8 at 2:59 PM
$SGMT nice move today
0 · Reply
focafoca99
focafoca99 Apr. 6 at 6:23 PM
$SGMT is combining science and HR here, highlighting upcoming MASH presentations while also disclosing an inducement grant.
0 · Reply
Biostock
Biostock Apr. 6 at 5:12 PM
$SGMT 27. MASH and ACNE. Billions in TAM. $XBI $LABU $SPY $QQQ up
0 · Reply
julsa
julsa Apr. 6 at 4:50 PM
$SGMT https://ir.sagimet.com/news-releases/news-release-details/sagimet-biosciences-announces-poster-and-oral-presentations
0 · Reply
DARKP00L
DARKP00L Apr. 6 at 11:15 AM
$SGMT 07:09 on Apr. 06 2026 Sagimet to Share Mid-Stage Liver Disease Drug Data at Medical Conference #tradeideas
0 · Reply
nastento
nastento Apr. 2 at 9:37 AM
$SGMT if anyone wants a laugh read what they put a hold rating and PT of 8🤣 they base if off insiders selling a few thousand shares (as scheduled) and their EPS is at a loss. Lmao ppl like these shouldnt have a job.
4 · Reply
nastento
nastento Mar. 31 at 2:11 PM
$SGMT i forget how tiny this biotech stock really is. Only 32 O.S., its so sensitive to any macro influence
0 · Reply
The_Horologist
The_Horologist Mar. 31 at 3:14 AM
$SGMT 😂😂😂😂
1 · Reply
Whiskeyunderthebed
Whiskeyunderthebed Mar. 30 at 5:47 PM
$SGMT anybody adding in here or waiting for it to go lower?
4 · Reply
MrBruceWayne
MrBruceWayne Mar. 30 at 5:20 PM
🚨💎 BUY ALERT $SGMT
0 · Reply
galaxySky
galaxySky Mar. 27 at 6:15 PM
$SGMT macro aside the catalysts: New/Unseen data from approvals: 1. AAD this weekend 2. EASL End of May H2 - Massive catalysts from acne, to further combo, china payments etc Buyout Rumors: - March/Now, MDGL ; any news there is going to be massive for us for anyone that knows anything about TAPI and our 20 variations, can’t imagine a rerating to at least 7+ won’t happen if anything moves here Macro is volatile af, but lots to look forward to
0 · Reply
rahmanoof
rahmanoof Mar. 27 at 5:26 PM
$SGMT earning Monday?
0 · Reply
nastento
nastento Mar. 27 at 1:40 PM
$SGMT lol i thought it was going to 3 john wick?
3 · Reply
Whiskeyunderthebed
Whiskeyunderthebed Mar. 26 at 8:47 PM
$SGMT
0 · Reply
nastento
nastento Mar. 26 at 7:16 PM
$SGMT MDGL potentially being taken out affecting us??
1 · Reply
rational1
rational1 Mar. 26 at 6:51 PM
$SGMT R&R initiates w/ Buy & $28 px tgt
1 · Reply